Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 286

    1.

    Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

    Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C, González-Amaro R.

    Arthritis Res Ther. 2006;8(3):R83. Epub 2006 May 5.

    PMID:
    16677395
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

    Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.

    Arthritis Rheum. 2007 Apr;56(4):1263-72.

    PMID:
    17393458
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

    Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.

    Arthritis Rheum. 2005 Feb;52(2):501-13.

    PMID:
    15693003
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.

    J Rheumatol. 2008 May;35(5):826-33. Epub 2008 Apr 1.

    PMID:
    18398943
    [PubMed - indexed for MEDLINE]
    5.

    Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.

    Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, Rémy P, Zarrouk V, Pillebout E, Jacquot C, Boffa JJ, Karras A, Masse V, Lesavre P, Elie C, Brocheriou I, Knebelmann B, Noël LH, Fakhouri F.

    Clin J Am Soc Nephrol. 2009 Mar;4(3):579-87. Epub 2009 Mar 4.

    PMID:
    19261822
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    B-cell-targeted therapy for systemic lupus erythematosus.

    Sabahi R, Anolik JH.

    Drugs. 2006;66(15):1933-48.

    PMID:
    17100405
    [PubMed - indexed for MEDLINE]
    7.

    Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

    Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, Leung YY, Wong KC, Szeto CC.

    Rheumatology (Oxford). 2009 Aug;48(8):892-8. Epub 2009 May 28.

    PMID:
    19478041
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.

    Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.

    Lupus. 2010 Feb;19(2):213-9. Epub 2009 Dec 4.

    PMID:
    19965944
    [PubMed - indexed for MEDLINE]
    9.

    Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.

    Marks SD, Tullus K.

    Paediatr Drugs. 2007;9(6):371-8. Review.

    PMID:
    18052407
    [PubMed - indexed for MEDLINE]
    10.

    Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

    Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN.

    Clin Immunol. 2007 Apr;123(1):66-73. Epub 2007 Jan 31.

    PMID:
    17275413
    [PubMed - indexed for MEDLINE]
    11.

    Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report.

    Edelbauer M, Jungraithmayr T, Zimmerhackl LB.

    Pediatr Nephrol. 2005 Jun;20(6):811-3. Epub 2005 Mar 17.

    PMID:
    15772840
    [PubMed - indexed for MEDLINE]
    12.

    Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.

    Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP.

    Nephrol Dial Transplant. 2009 Jul;24(7):2157-60. Epub 2009 Jan 29.

    PMID:
    19179411
    [PubMed - indexed for MEDLINE]
    Free Article
    13.

    Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis.

    Vigna-Pérez M, Abud-Mendoza C, Portillo-Salazar H, Alvarado-Sánchez B, Cuevas-Orta E, Moreno-Valdés R, Baranda L, Paredes-Saharopulos O, González-Amaro R.

    Clin Exp Immunol. 2005 Aug;141(2):372-80.

    PMID:
    15996202
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.

    Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.

    Rheumatology (Oxford). 2005 Feb;44(2):176-82. Epub 2004 Oct 19.

    PMID:
    15494350
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    [Interleukin 10 in disseminated lupus erythematosus].

    Emilie D.

    J Soc Biol. 2002;196(1):19-21. Review. French.

    PMID:
    12134628
    [PubMed - indexed for MEDLINE]
    16.

    A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.

    Boumpas DT, Tassiulas IO, Fleisher TA, Vaughan E, Piscitelli S, Kim Y, Pucino F, Balow JE, Austin HA.

    Clin Nephrol. 1999 Aug;52(2):67-75.

    PMID:
    10480216
    [PubMed - indexed for MEDLINE]
    17.

    A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.

    Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T.

    Mod Rheumatol. 2007;17(3):191-7. Epub 2007 Jun 20.

    PMID:
    17564773
    [PubMed - indexed for MEDLINE]
    18.

    B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.

    Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K.

    Arch Dis Child. 2008 May;93(5):401-6. Epub 2007 Nov 26.

    PMID:
    18039744
    [PubMed - indexed for MEDLINE]
    19.

    Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.

    Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT.

    Arthritis Res Ther. 2009;11(4):R131. Epub 2009 Aug 28.

    PMID:
    19715572
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

    Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, Lightstone L, Cairns T.

    Nephrol Dial Transplant. 2009 Dec;24(12):3717-23. Epub 2009 Jul 17.

    PMID:
    19617257
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk